Free Trial
NASDAQ:MRKR

Marker Therapeutics (MRKR) Stock Price, News & Analysis

Marker Therapeutics logo
$0.87 -0.03 (-3.33%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.93 +0.06 (+7.36%)
As of 11/13/2026 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Marker Therapeutics Stock (NASDAQ:MRKR)

Advanced

Key Stats

Today's Range
$0.87
▼
$0.93
50-Day Range
$0.87
▼
$1.28
52-Week Range
$0.87
▼
$2.46
Volume
76,084 shs
Average Volume
146,045 shs
Market Capitalization
$14.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Moderate Buy

Company Overview

Marker Therapeutics is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. Its platform aims to produce T cells that recognize multiple tumor-associated antigens, with the goal of helping them target cancer cells while reducing the risk that tumors evade treatment by losing a single antigen.

The company’s pipeline includes multi-antigen-specific T-cell candidates for blood cancers. Its programs have included MT-601, studied for lymphoma, and MT-401, developed for acute myeloid leukemia and other hematologic malignancies. These candidates are investigational and remain in clinical development.

Marker Therapeutics was formed in 2018 through a merger involving TapImmune and Marker Therapeutics, Inc.; TapImmune subsequently adopted the Marker Therapeutics name. The company is based in Houston, Texas, and its development work centers on advancing cell-based cancer treatments.

AI Generated. May Contain Errors.

Marker Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

MRKR MarketRank™: 
2.79539473684 of 5 stars

Marker Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 444th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Marker Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Marker Therapeutics has a consensus price target of $10.00, representing about 1,049.4% upside from its current price of $0.87.

  • Amount of Analyst Coverage

    Marker Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Marker Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.64) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Marker Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Marker Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Marker Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.12% of the float of Marker Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Marker Therapeutics has a short interest ratio ("days to cover") of 0.69, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Marker Therapeutics has recently increased by 61.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Marker Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Marker Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Marker Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Marker Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for MRKR on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Marker Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.70% of the stock of Marker Therapeutics is held by insiders.

  • Percentage Held by Institutions

    22.39% of the stock of Marker Therapeutics is held by institutions.

  • Read more about Marker Therapeutics' insider trading history.
Receive MRKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRKR Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Marker Therapeutics Sets Date for 2026 Annual Meeting
See More Headlines

MRKR Stock Analysis - Frequently Asked Questions

Marker Therapeutics' stock was trading at $1.49 on January 1st, 2026. Since then, MRKR shares have decreased by 41.6% and is now trading at $0.87.

Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.16.

Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Viking Therapeutics (VKTX), AT&T (T), Tesla (TSLA) and Netflix (NFLX).

Company Calendar

Last Earnings
8/14/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MRKR
CIK
1094038
Fax
N/A
Employees
5
Year Founded
2018

Price Target and Rating

High Price Target
$10.00
Low Price Target
$10.00
Potential Upside/Downside
+1,049.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.16 million
Net Margins
N/A
Pretax Margin
-373.37%
Return on Equity
-56.96%
Return on Assets
-47.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.03
Quick Ratio
6.03

Sales & Book Value

Annual Sales
$3.55 million
Price / Sales
4.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.01 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
16,670,000
Free Float
15,723,000
Market Cap
$14.50 million
Optionable
Not Optionable
Beta
1.65

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:MRKR) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners